Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ. |  |
|
|
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Duato Joaquin | CEO and Chairman of the Board | Feb 07 '25 | Option Exercise | 100.06 | 126,369 | 12,644,482 | 489,671 | Feb 11 07:43 PM | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Feb 07 '25 | Option Exercise | 100.06 | 32,762 | 3,278,166 | 115,028 | Feb 11 07:42 PM | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Feb 07 '25 | Option Exercise | 100.06 | 58,504 | 5,853,910 | 213,355 | Feb 11 07:41 PM | Wolk Joseph J | Exec VP, CFO | Feb 07 '25 | Option Exercise | 100.06 | 13,015 | 1,302,281 | 13,015 | Feb 11 07:40 PM | Wolk Joseph J | Exec VP, CFO | Feb 07 '25 | Sale | 153.89 | 13,015 | 2,002,878 | 0 | Feb 11 07:40 PM | Wolk Joseph J | Officer | Feb 07 '25 | Proposed Sale | 153.89 | 13,015 | 2,002,924 | | Feb 07 01:27 PM | WEINBERGER MARK A | Director | Dec 12 '24 | Buy | 147.22 | 1,000 | 147,220 | 1,000 | Dec 12 05:27 PM | Hait William | Former Officer | Dec 04 '24 | Proposed Sale | 149.90 | 25,742 | 3,858,598 | | Dec 04 01:25 PM | Decker Robert J | VP Corporate Controller | Aug 30 '24 | Option Exercise | 100.06 | 5,635 | 563,838 | 24,608 | Sep 03 04:48 PM | Decker Robert J | VP Corporate Controller | Aug 30 '24 | Sale | 165.06 | 5,635 | 930,113 | 18,973 | Sep 03 04:48 PM | Decker Robert J | Officer | Aug 30 '24 | Proposed Sale | 165.06 | 5,635 | 930,113 | | Aug 30 03:51 PM | Broadhurst Vanessa | EVP, Global Corp Affairs | Jul 08 '24 | Option Exercise | 0.00 | 9,809 | 0 | 24,852 | Jul 09 05:48 PM | REED JOHN C | EVP, Innovative Medicine, R&D | May 01 '24 | Option Exercise | 0.00 | 22,255 | 0 | 22,561 | May 03 04:31 PM | Broadhurst Vanessa | EVP, Global Corp Affairs | Mar 13 '24 | Sale | 162.16 | 8,891 | 1,441,765 | 15,043 | Mar 13 04:36 PM | JOHNSON & JOHNSON | 10% Owner | Feb 29 '24 | Option Exercise | 0.72 | 3,855 | 2,792 | 4,103,430 | Mar 06 03:42 PM | JOHNSON & JOHNSON | 10% Owner | Feb 16 '24 | Sale | 25.81 | 3,725 | 96,142 | 4,099,575 | Mar 06 03:42 PM | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Feb 13 '24 | Option Exercise | 0.00 | 651 | 0 | 82,599 | Feb 15 04:53 PM | Wolk Joseph J | Exec VP, CFO | Feb 13 '24 | Option Exercise | 0.00 | 1,780 | 0 | 69,663 | Feb 15 04:53 PM | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Feb 13 '24 | Option Exercise | 0.00 | 1,302 | 0 | 155,517 | Feb 15 04:53 PM | Swanson James D. | EVP, CIO | Feb 13 '24 | Option Exercise | 0.00 | 447 | 0 | 14,765 | Feb 15 04:53 PM | Schmid Timothy | EVP, WW Chair, MedTech | Feb 13 '24 | Option Exercise | 0.00 | 499 | 0 | 13,290 | Feb 15 04:53 PM | Fasolo Peter | Exec VP, Chief HR Officer | Feb 13 '24 | Option Exercise | 0.00 | 925 | 0 | 112,550 | Feb 15 04:53 PM | Hait William | See Remarks | Feb 13 '24 | Option Exercise | 0.00 | 834 | 0 | 39,074 | Feb 15 04:53 PM | Duato Joaquin | CEO and Chairman of the Board | Feb 13 '24 | Option Exercise | 0.00 | 3,470 | 0 | 364,809 | Feb 15 04:53 PM | Broadhurst Vanessa | EVP, Global Corp Affairs | Feb 13 '24 | Option Exercise | 0.00 | 408 | 0 | 24,143 | Feb 15 04:53 PM | Forminard Elizabeth | Executive VP, General Counsel | Feb 13 '24 | Option Exercise | 0.00 | 651 | 0 | 8,576 | Feb 15 04:53 PM | Decker Robert J | VP Corporate Controller | Feb 13 '24 | Option Exercise | 0.00 | 313 | 0 | 19,059 | Feb 15 04:53 PM |
|